Five IPOs raised $1.4 billion this week, bringing the year's total up to 50 IPOs raising $15 billion. Set to be the week's largest offerings, two energy companies struggled: Antero Midstream GP broke issue while Liberty postponed. A mortgage REIT and...read more
Biohaven Pharmaceuticals Holding, which is developing treatments for migraine and neurological disorders, raised $168 million by offering 9.9 million shares at $17, above the range of $14 to $16. Biohaven Pharmaceuticals plans to list on the NYSE under the...read more
The IPO market continues to heat up with six deals on the calendar aiming to raise $1.7 billion in the first week of May. They include three biotechs, two energy companies and one mortgage REIT. This April was the busiest month for IPOs in almost two years, and ...read more
Biohaven Pharmaceuticals, which is developing treatments for neurological diseases and rare disorders, announced terms for its IPO on Monday.
The New Haven, CT-based company plans to raise $125 million by offering 8.3 million shares at a price range of $14 ...read more
US IPO Weekly Recap: Biotechs and energy fail to excite in 5-IPO week
Five IPOs raised $1.4 billion this week, bringing the year's total up to 50 IPOs raising $15 billion. Set to be the week's largest offerings, two energy companies struggled: Antero Midstream GP broke issue while Liberty postponed. A mortgage REIT and...read more
Migraine biotech Biohaven Pharmaceuticals prices upsized IPO above the range at $17
Biohaven Pharmaceuticals Holding, which is developing treatments for migraine and neurological disorders, raised $168 million by offering 9.9 million shares at $17, above the range of $14 to $16. Biohaven Pharmaceuticals plans to list on the NYSE under the...read more
US IPO Week Ahead: May starts strong with 6 IPOs featuring energy and biotech
The IPO market continues to heat up with six deals on the calendar aiming to raise $1.7 billion in the first week of May. They include three biotechs, two energy companies and one mortgage REIT. This April was the busiest month for IPOs in almost two years, and ...read more
Rare disease biotech Biohaven Pharmaceuticals sets terms for $125 million IPO
Biohaven Pharmaceuticals, which is developing treatments for neurological diseases and rare disorders, announced terms for its IPO on Monday. The New Haven, CT-based company plans to raise $125 million by offering 8.3 million shares at a price range of $14 ...read more